Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

NCT02633020 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Type II Refractory Celiac Disease (RCD-II)
In-situ Small Bowel T-cell Lymphoma

Interventions

BIOLOGICAL: AMG 714
BIOLOGICAL: Placebo

Sponsor

Amgen